Insulet Reports Third Quarter 2024 Revenue Increase of 26% Year-Over-Year (25% Constant Currency¹)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. PFE
9. AWK
10. ACN

Go back to Insulet Reports Third Quarter 2024 Revenue Increase of 26% Year-Over-Year (25% Constant Currency¹)

Insulet Corporation (PODD) PT Raised to $234 at Barclays

November 11, 2024 5:53 AM EST

Barclays analyst Matt Miksic raised the price target on Insulet Corporation (NASDAQ: PODD) to $234.00 (from $220.00) while maintaining a Equalweight rating.

The analyst comments "PODD Rallies on Q3 Beat, Fueled by International (+$19MM), Drug Delivery (+$7MM) and Rising Expectations for the T2 Pump Launch: Mgmt delivered a strong beat to vs. our estimates and Bloomberg... More

Insulet Corporation (PODD) PT Raised to $270 at BTIG

November 8, 2024 5:13 AM EST

BTIG analyst Marie Thibault raised the price target on Insulet Corporation (NASDAQ: PODD) to $270.00 (from $260.00) while maintaining a Buy rating.

The analyst comments "Insulet reported Q3 revenue of $543.9M (+25.7% y/y), beating consensus estimates of $519.5M and exceeding the ~$510-$524M sales guide. This was driven by a large beat in International Omnipod sales. U.S. Omnipod revenue of $395.6M came in ~$4M higher than expected (cons. $391.9M) while OUS Omnipod revenue of $138M was ~$15M above the Street's forecast (cons. $123.3M). Drug Delivery sales were $10.3M. The full year sales guide... More